GlassScriptPhysician profile
Lisa Redden
NPI 1447614409
$834.89
in general payments reported to CMS, 2019-2025
18 companies · $99.32 in 2025
The $99.32 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $108 · 2024: $628 · 2025: $99.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $121.90 | 2023-2024 | Opdualag, Opdivo, Augtyro |
| Glaxosmithkline, LLC. | $98.76 | 2023-2025 | Ojjaara |
| Janssen Biotech, INC. | $87.24 | 2024 | Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $83.45 | 2024 | |
| Abbvie INC. | $54.20 | 2024-2025 | |
| Pfizer INC. | $46.15 | 2024 | |
| Eisai INC. | $44.67 | 2023-2024 | |
| Tempus Ai, INC | $43.41 | 2024-2025 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $38.74 | 2024 | |
| Genentech USA, INC. | $35.88 | 2024 | Venclexta, Columvi, Polivy |
| Beigene USA, INC. | $33.94 | 2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $27.87 | 2025 | Keytruda |
| Celgene Corporation | $22.34 | 2024 | Reblozyl |
| Incyte Corporation | $20.58 | 2024 | Jakafi |
| Seagen INC. | $20.14 | 2023 | Tivdak |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $18.80 | 2024 | Ultomiris |
| Astellas Pharma US INC | $18.51 | 2024 | Padcev |
| Gilead Sciences, INC. | $18.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Redden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.